Comparison of baseline demographic, clinical and laboratory features between patients treated with colchicine plus (+) standard-of-care (SoC) or with SoC only
Clinical features | Colchicine + SoC, n=122 | SoC, n=140 | P value |
Male (%) | 77 (63) | 90 (64) | 0.84 |
Age (years), mean (SD) | 69.3 (9.6) | 70.5 (13.8) | 0.12 |
Period of observation (days), mean (SD) | 21.3 (6.8) | 25.0 (14.8) | 0.012 |
Smokers or previous smokers (%) | 21/96 (22) | 18/113 (16) | 0.37 |
Cardiovascular comorbidities* (%) | 65/101 (64) | 85/115 (74) | 0.22 |
Chronic obstructive bronchopneumonia (%) | 17/103 (17) | 24/111 (22) | 0.34 |
History of malignanicies (%) | 9/104 (9) | 24/116 (21) | 0.013 |
Ever treated with hydroxychloroquine (%) | 46/102 (45) | 78/138 (57) | 0.08 |
Ever treated with lopinavir/ritonavir (%) | 10/106 (9) | 53/139 (38) | <0.0001 |
Ever treated with dexamethasone (%) | 62/107 (58) | 44/139 (32) | <0.0001 |
PaO2/FiO2 (mm Hg/%), mean (SD) | 176.6 (81) | 244.9 (106) | <0.0001 |
Ferritin (ng/mL), mean (SD) | 1987 (1983) | 1130 (1104) | 0.0005 |
C reactive protein (mg/L), mean (SD) | 159.0 (92.9) | 112.5 (82.6) | 0.0003 |
Neutrophil count (cell/µL), mean (SD) | 6859 (4070) | 5844 (3786) | 0.022 |
Lymphocyte count (cell/µL), mean (SD) | 921 (427) | 1016 (660) | 0.75 |
*Cardiovascular comorbidities: any history of cardiovascular disease, including coronary heart disease (ie, myocardial infarction, angina and coronary revascularisation), cerebrovascular disease (ie, stroke and transient ischaemic attack) and/or peripheral arterial disease, diabetes mellitus and arterial hypertension.